Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07224529 · ClinicalTrials.gov registry record · Phase 4
Efficacy of Vevye Ophthalmic Solution for the Treatment of Meibomian Gland Dysfunction
A Phase 4 study, sponsored by University of Alabama at Birmingham.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 48
- Enrollment target
NCT07224529 is a Phase 4 study that is actively recruiting participants, run by University of Alabama at Birmingham. The registered enrollment target is 48 participants.
The verdict
NCT07224529, a Phase 4 study, is actively recruiting participants, sponsored by University of Alabama at Birmingham.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 48 participants
- Enrollment target
Study Summary
This research study evaluates a prescription eye drop called Vevye® (cyclosporine 0.1%) for adults who have meibomian gland dysfunction (MGD), a common eye condition that can cause dry, irritated, or burning eyes. If you join the study, after a short "run-in" period using artificial tears, you will receive Vevye twice a day for about 24 weeks (approximately six months). During that time you will attend several clinic visits where your eye symptoms, lid health, tear film, and meibomian gland function will be assessed. The goal is to learn whether Vevye improves symptoms (like eye dryness or irritation) and signs (such as changes on the eye's surface or lid margins) of MGD. You will also be monitored for safety and comfort of the eye drop. The information obtained from this study may help determine whether this treatment is beneficial for people with this condition and contribute to future care options. Participation is voluntary and you may stop at any time.
Interventions
- DRUG Vevye(Cyclosporine 0.1% Ophthalmic Solution)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2026-06-01 |
| Est. Completion | 2027-02-01 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07224529
The ClinicalTrials.gov registry entry for NCT07224529 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Alabama at Birmingham, which has 1,160 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Vevye(Cyclosporine 0.1% Ophthalmic Solution) is the first listed.
NCT07224529 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07224529 about?
NCT07224529 is a clinical study titled "Efficacy of Vevye Ophthalmic Solution for the Treatment of Meibomian Gland Dysfunction". This research study evaluates a prescription eye drop called Vevye® (cyclosporine 0.1%) for adults who have meibomian gland dysfunction (MGD), a common eye condition that can cause dry, irritated, or burning eyes. If you join the study, after a short "run-in" period using artificial tears, you will...
What is the current status of trial NCT07224529?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 48 participants. The study started on 2026-06-01. Estimated completion is 2027-02-01.
What interventions are being tested in trial NCT07224529?
The interventions under investigation include: Vevye(Cyclosporine 0.1% Ophthalmic Solution) (DRUG).
Who is sponsoring clinical trial NCT07224529?
This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.